Home › Funds › Putnam › Putnam Global Health Care Fund
Fund family: Putnam · Filed by PUTNAM GLOBAL HEALTH CARE FUND (CIK 357295) · SEC series S000005666
Share classes and tickers: PCHSX (C000015517), PHSBX (C000015516), PHSRX (C000015519), PHSTX (C000015515), PHSYX (C000015520)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 431 with, 18 against, 8 abstentions (not counted as with management); 5 items carried no recommendation. Shareholder proposals: 1 FOR, 17 AGAINST, 5 abstained, by the filing’s own vote-source field.
The same two figures as Putnam’s manager page (91,627 ballot items across 55 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Putnam | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 95.7% | 414 | 92.4% | 79,249 |
| Backed environmental and social shareholder proposals at US companies | n/a | 7 | 0.7% | 1,753 |
Each ballot item this fund voted is set against the votes of the other Putnam funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Putnam funds on 1 item (0.2% of the 415 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Putnam funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 2026-04-30 | Shareholder To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. | Against | FOR — 5 of 9 Putnam funds | For | Not approved, 27.1% support |
Download all 1 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 71.1% of this fund’s 457 such votes could be given a sector; the other 132 (28.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 295 | 17 | 5.8% |
| Consumer Staples | 17 | 1 | 5.9% |
| Industrials | 13 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 305 | 0 |
| Audit-related | 34 | 0 |
| Compensation | 34 | 0 |
| Corporate Governance | 32 | 11 |
| Say-on-Pay | 27 | 0 |
| Capital Structure | 20 | 0 |
| Other Social Issues | 6 | 4 |
| Environment or Climate | 3 | 3 |
| Other | 1 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $246M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $161M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $120M | 8 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $110M | 12 | 1 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $93M | 13 | 0 |
| McKesson Corporation | July 30, 2025 | $88M | 14 | 0 |
| Merck & Co., Inc. | May 26, 2026 | $87M | 18 | 3 |
| Intuitive Surgical, Inc. | April 30, 2026 | $54M | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
These funds reported the same votes as Putnam Global Health Care Fund in the latest season, so they share this page:
463 ballot items at 37 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Putnam Global Health Care Fund (PCHSX) voted at 37 shareholder meetings of 34 companies, on 463 ballot items in all. Where management made a recommendation, the fund followed it on 94.3% of the items and voted against it 18 times. Its most frequent area of disagreement was corporate governance (11 of its votes against management). It voted on 23 shareholder proposals. It voted FOR the board's own proposals more often than Putnam's funds as a whole (95.7% against 92.4%). It voted differently from most Putnam funds on 1 item.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Putnam’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.